A blood test reported at AAIC 2026 can estimate how likely someone is to develop cognitive impairment years before symptoms appear, but it was built and tested in people who were cognitively healthy, not in people already diagnosed with mild cognitive impairment (MCI). If you or someone you care for already has an MCI diagnosis, the study's risk percentages describe a different population, and applying them to yourself directly will overstate or understate what they mean for your situation. The findings come from a JAMA study led by Rachel F.
Buckley of Mass General Brigham and Harvard, presented at the Alzheimer's Association International Conference in London and detailed in the AAIC press release. It measured a blood marker called p-tau217, a fragment of the tau protein linked to Alzheimer's disease, in people who had no cognitive symptoms at enrollment. What it found is genuinely useful for counseling — but only once you understand what it did and didn't measure.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the study actually found
- Why this doesn't map onto an existing MCI diagnosis
- Where blood biomarker testing does have a defined role right now
- What proper disclosure of a result should look like
- Frequently Asked Questions
What the study actually found
Researchers followed roughly 2,700 cognitively unimpaired older adults, average age 70, across five to six research cohorts, tracking who later progressed to cognitive impairment, according to HealthDay's coverage of the AAIC presentation. Higher plasma p-tau217 at baseline predicted a greater chance of later developing MCI, dementia, or a CDR score of 0.5 (a standard clinical marker of mild symptoms). The hazard ratio was 1.38 for each standard-deviation increase in the marker, and it stayed significant at 1.32 after accounting for amyloid PET scan results, per the AAIC press release. Translated into absolute terms, people with very high p-tau217 levels had about a 38% chance of progressing to cognitive impairment within 5 years and about 78% within 10 years.
Those with moderately elevated levels had roughly 15% (5-year) and 45% (10-year) risk, the AAIC release reported. These are population averages drawn from study cohorts, not a certainty for any one individual. The 10-year, 78% figure gets quoted the most because it sounds dramatic, but it comes from a smaller subgroup with long-term follow-up data and carries more statistical uncertainty than the 5-year number, a limitation noted in coverage from Patient Care Online. Treat the 10-year estimate as a rougher signal than the 5-year one.
Why this doesn't map onto an existing MCI diagnosis
The study's entire point was predicting who would move from no symptoms to symptoms. If you've already been diagnosed with MCI, you're past that starting line — the 5-year and 10-year percentages describe a transition you've already made, not one still ahead of you. A commentary from Spain's Science Media Centre, reviewing the same AAIC findings, stressed that MCI is a risk state rather than established dementia, and that these prediction figures require careful translation into real-world situations rather than a direct read-across, according to that expert commentary. The same commentary flagged a second limit worth carrying into any conversation with a clinician: p-tau217 signals Alzheimer's-related brain changes specifically.
It says nothing about other causes of cognitive symptoms, such as vascular disease, Lewy body changes, or medication effects, which also produce MCI. A high p-tau217 result in someone with MCI may point toward an Alzheimer's process underlying their symptoms, but it isn't a stand-in for a full diagnostic workup. Separately at AAIC 2026, Eli Lilly reported that p-tau217 blood tests performed comparably to amyloid PET scans at ruling in Alzheimer's pathology, with positive predictive values above 83% in nearly 790 cognitively unimpaired participants. Even with that strong performance, Lilly's own researchers stated such tests are not currently indicated for use in people without symptoms, according to the BioSpace report on Lilly's AAIC data. That caution was built for symptom-free people; it doesn't automatically carry over to someone already diagnosed with MCI, where the test serves a different purpose.
Where blood biomarker testing does have a defined role right now
For people who have already been evaluated for cognitive symptoms — including an MCI diagnosis — blood-based biomarker testing has a specific, defined use, laid out in the Alzheimer's Association's first clinical practice guideline on these tests. Tests that meet a sensitivity of at least 90% and specificity of at least 75% can serve as a triage tool, helping decide who needs further workup. Tests meeting a higher bar — at least 90% on both measures — can replace confirmatory testing like amyloid PET scans or spinal fluid analysis, according to reporting on the guideline from Patient Care Online.
That guideline comes with an explicit caveat: not every commercial blood test on the market meets those accuracy thresholds. Two tests can share a name — "p-tau217 blood test" — and differ meaningfully in how reliable their results are. This is the question worth asking a clinician directly: does the specific test being ordered meet the triage threshold, the replacement threshold, or neither.
- Ask which accuracy tier the specific test falls into (triage-level or replacement-level), not just whether a test was done.
- Ask what the result changes about the clinical plan — further testing, a specialist referral, or nothing.
- Ask whether the result is being used to explain existing MCI symptoms, or to predict whether MCI will develop in someone without symptoms — these are different uses of the same marker.
What proper disclosure of a result should look like
Because a biomarker result carries real emotional weight, professional guidance exists on how it should be delivered. A joint panel convened by the European Academy of Neurology and the European Alzheimer's Disease Consortium recommends that a dementia specialist, not a general practitioner or a lab report alone, handle the disclosure of biomarker results. The guidance calls for counseling both before and after the test — covering the pros, cons, and alternatives to testing — along with written information to take home and an explicit follow-up plan, according to the Frederiksen et al. guidance published in the European Journal of Neurology. One point in that guidance is easy to overlook in a rushed appointment: the specialist should explicitly clarify that MCI is not dementia.
The two are frequently conflated in casual conversation and even in media coverage of studies like this one, but they carry different prognoses, different support needs, and different next steps. If a result comes back and that distinction isn't made clearly, it's a fair thing to ask about directly. A positive or elevated biomarker result also doesn't currently change what can be done about it. Researchers behind the AAIC findings said it remains premature to use p-tau217 testing for routine screening of symptom-free people outside of research settings, specifically because no preventive treatment exists yet to act on a positive result, per HealthDay's report. For someone with an existing MCI diagnosis, the test's value lies in sharpening the diagnostic picture and guiding monitoring — not in changing a treatment that doesn't yet exist for the underlying biology.
Frequently Asked Questions
Does a high p-tau217 result mean someone with MCI will definitely develop dementia?
No. The AAIC risk percentages (such as 38% at 5 years for very high levels) are population-level estimates from people who started with no symptoms, not individual guarantees, and they don't directly apply to someone who already has an MCI diagnosis, per the AAIC press release.
Can a blood test replace a PET scan or spinal fluid test for someone with MCI?
Only if the specific test meets the Alzheimer's Association guideline's higher accuracy bar — at least 90% sensitivity and 90% specificity. Lower-performing tests are meant for triage, not replacement, according to Patient Care Online's coverage of the guideline.
Who should explain a biomarker test result to a patient?
European disclosure guidance recommends a dementia specialist deliver the result, with counseling before and after the test and a clear follow-up plan, per Frederiksen et al.
You Might Also Like
- The AAIC 2026 Swedish Real-World Blood Test Study: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- AAIC 2026 Evidence on Blood Tests and Diagnostic Plans: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: What Researchers Still Need to Learn for Adults With Memory Concerns
